Science

Articles

• Society for the study of Blood-Brain interfaces SEISC 2019 congres
  27 November 2019, by Elodie DORMES

  Stéphane GIRARD will present iPS cell-derived model of the human blood-brain-barrier on Friday 15, Nov Session 1 of the Society for the study of Blood-Brain interfaces SEISC 2019 congres in Paris

• TIDES Asia, March 2-5 2021 - 100% Virtual
  4 March 2021, by Elodie DORMES

  Guillaume JACQUOT PharmD, PhD, will present last company results on extra-hepatic delivery of oligonucleotides.

• Neurotensin, vectorised by VECT-HORUS, is the first drug-candidate in neuroprotective hypothermia
  28 January 2019, by Jonathan NOWAK

  VECT-HORUS starts the regulatory preclinical development of VH-N439, positioned as a first-in-class neuroprotective agent in brain ischemia Neurotensin is a neuropeptide with global hypothermic potential when administered directly into the brain, but unable to cross the blood-brain barrier (BBB) when administrated alone systemically. The Company has developed VH-N439, a new chemical entity based on the conjugation of one of its peptide-vectors to an analogue of neurotensin.
  Using in vivo (…)

• Séminaire M&M’s – Muscle Monday Seminars of the Institute’s Myology Centre for Research on January 17, 2022
  17 January 2022, by Elodie DORMES

  Michel Khrestchatisky (CNRS Research Director, Director of the Institute for Neurophysiopathology) Co-Founder & Scientific Counsel of Vect-Horus presents "Development of molecular vectors for targeted delivery of RNAi via receptor-mediated transport" at the Muscle Monday Seminars organized by the Institute’s Myology Centre for Research.

• TIDES Europe: Oligonucleotide & Peptide Therapeutics in AMSTERDAM
  31 October 2019, by Elodie DORMES

  Dr Guillaume JACQUOT will present "Targeted Drug Delivery to the CNS and Peripheral Tissues Using the VECTrans® Innovative Technology" during the TIDES Europe, 12-15 November 2019.

• Vect-Horus and RadioMedix Announce FDA Approval of Exploratory IND of Diagnostic 68 Ga-RMX-VH in Glioblastoma Multiforme
  8 July 2021, by Elodie DORMES

  Vect-Horus and RadioMedix are pleased to announce the FDA clearance of eIND application to evaluate 68Ga-RMX-VH for the diagnostic of GBM.

• Festival of Biologics 2019 in BASEL
  31 October 2019, by Elodie DORMES

  Meet with Pascaline LECORCHE during the Festival of Biologics 2019, 15 – 17 October 2019 _ Basel Switzerland and discuss on « Design of peptide-based vectors for targeted delivery ».

• Vect-Horus team will attend the 8AIS2020 symposium from Nov. 23-26, 2020
  12 November 2020, by Elodie DORMES

  Marion DAVID will be presenting a poster entitled “Development of versatile single domain antibody vectors that enhance brain deliver of antibodies by targeting the TfR transport system. ”
  Please use the partnering system to contact us and organize a 1&1 meeting : www.aiscongress.com

• Vect-Horus validates the potential of its peptide vectors to transport proteins or antibodies, across the blood-brain barrier via receptor mediated transport
  28 January 2019, by Jonathan NOWAK

  (Molino et al., 2017, The FASEB Journal)
  www.fasebj.org/content/early/2017/01/19/fj.201600827R.abstract

• LDL receptor-peptide conjugate as in vivo tool for specific targeting of pancreatic ductal adenocarcinoma
  30 September 2021, by Elodie DORMES

  Vect-Horus is proud to be part of the research in PDAC with its theranostic agents to first improve PDAC diagnosis, response monitoring or recurrence detection in operated patients and also treat them.
  Cedric malicet, Oncology Department Manager, is pleased to inform you of the recent publication of the article “ LDL receptor-peptide conjugate as in vivo tool for specific targeting of pancreatic ductal adenocarcinoma “ in Communications Biology.